3KY.F HANSOH PHARMAC. HD-00001
- Market cap
- EUR 23.6B
- P/E
- 27.8x
- P/B
- 4.72x
- ROE
- 15.7%
- Dividend yield
- 1.42%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 3KY.F undervalued?
Graham number3KY.F trades 141.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HANSOH PHARMAC. HD-00001 fundamental analysis
No fundamental analysis for HANSOH PHARMAC. HD-00001 yet.
HANSOH PHARMAC. HD-00001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pula…
Full company profileHANSOH PHARMAC. HD-00001 financial statements
HANSOH PHARMAC. HD-00001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 9.94B | 9.38B | 10.1B | 12.3B | 15.0B |
| Gross Profit | 9.07B | 8.52B | 9.07B | 11.2B | 13.5B |
| Operating Income | 3.03B | 2.79B | 2.84B | 4.03B | 5.55B |
| EBITDA | - | 3.35B | 4.20B | 5.49B | 6.95B |
| Net Income | 2.71B | 2.58B | 3.28B | 4.37B | 5.56B |
| EPS | 0.46 | 0.44 | 0.55 | 0.74 | 0.92 |
| Balance Sheet | |||||
| Total Assets | 27.2B | 30.0B | 33.0B | 31.7B | 39.9B |
| Total Liabilities | 7.13B | 7.35B | 7.24B | 2.98B | 4.54B |
| Shareholders' Equity | 20.0B | 22.6B | 25.8B | 28.7B | 35.4B |
| Cash & Short-term Investments | 14.7B | 17.6B | 22.4B | 22.6B | 31.5B |
| Cash Flow | |||||
| Operating Cash Flow | 2.58B | 2.74B | 3.12B | 3.86B | 6.74B |
| Capital Expenditure | 475M | 292M | 363M | 525M | 489M |
| Free Cash Flow | 2.10B | 2.45B | 2.75B | 3.34B | 6.25B |
| Ratios | |||||
| ROE | 13.5% | 11.4% | 12.7% | 15.2% | 15.7% |
| ROA | 10.0% | 8.6% | 9.9% | 13.8% | 13.9% |
| Net Profit Margin | 27.3% | 27.5% | 32.4% | 35.7% | 37.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
HANSOH PHARMAC. HD-00001 dividends
- Dividend yield
- 1.42%
- Forward dividend
- 0.05 EUR
- Payout ratio
- 36.2%
- Ex-dividend date
- Sep 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 2.01B | 0.33 | 36.2% |
| 2024 | CNY 1.86B | 0.31 | 42.5% |
| 2023 | CNY 652M | 0.11 | 19.9% |
| 2022 | CNY 712M | 0.12 | 27.6% |
| 2021 | CNY 381M | 0.06 | 14.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns HANSOH PHARMAC. HD-00001
- Insiders 79.55%
- Institutions 12.78%
- Public & others 7.67%
- Shares outstanding 6.06B
- Free float 1.25B
HANSOH PHARMAC. HD-00001 company profile
- Company name
- HANSOH PHARMAC. HD-00001
- Ticker
- 3KY.F
- ISIN
- KYG549581067
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9,643
- Fiscal year end
- December
- Address
- 287 Xiangke Road, Shanghai, China, 201210
- Phone
- 86 40 0828 5227
- Website
- hspharm.com
About HANSOH PHARMAC. HD-00001
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.
HANSOH PHARMAC. HD-00001 management
10- Ms. Huijuan ZhongFounder, Chairlady & CEO · born 1961
- Dr. Aifeng LyuExecutive Director · born 1977
- Ms. Yuan SunExecutive Director · born 1987
- Mr. Taisheng YuanChief Financial Officer
- Dr. Shan JiangChief Technology Officer · born 1970
- Dr. Chih-Hung LeeChief Science Officer · born 1961
- Dr. Weiyong SunChief Business Officer · born 1971
- Dr. Xiaoqing ZhangChief Medical Officer · born 1974
- Ms. Zhao ZengJoint Company Secretary
- Ms. Ying GuoJoint Company Secretary · born 1987